8th Pharmacovigilance 2015 24th & 25th February 2015, Marriott Marble Arch Hotel, London, UK
8th Annual Pharmacovigilance 2015 will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. The entire program will cover the detection, analysis and prevention of adverse drug reactions. It will be studied with the help of case studies and industry experiences. This conference will help the drug safety representatives from the pharmaceutical industry and academic and quality research organisations who wish to understand how to avoid common deficiencies in inspections by learning from the experiences of others; to gain a greater understanding of new and existing pharmacovigilance requirements, and to improve their organisations' compliance with pharmacovigilance requirements. Also it can help you control your product's lifecycle, your patient's trust, and your revenue. Hence, this conference will provide an important platform for pharmacovigilance stakeholders to discuss and share best practices in expediting pharmacovigilance development.
KEY THEMES:-
Update yourself with respect to terms of legislation, policies, systems, technology, communication strategies and best practice in PV
Developing Pharmacovigilance into high quality management system and its components
Audit and Inspection: Realistic steps for a fruitful consequence
EMA PSMF - Assuring compliance and provide standardization
Discover approaches for collecting, integrating and analyzing all of the safety data generated from preclinical models
Exploiting the pharmacy automations and technologies for enhancement of medication safety
Developments in Pharmacovigilance, drug safety & risk management to ensure safer drugs to market
Improving patient care and safety in relation to use of medicines and all medical and paramedical interventions
Determining the steps and strategies for enhancing quality in healthcare
Emerging signal detection data gathering successful tools to highlight emerging risks
IT solutions for Pharmacovigilance – Learn & Explore
Maintaining proper balance in relationships: Sponsor – Site – CRO & Patients
GVP Module V and XVI – explaining authority expectations and avoid speculation and differing interpretation of the current guidelines
Review the use of (PSURs) post-authorisation for safety signals
ICH-R3 standards - Determining where future challenges could arise
The developing regulatory framework in advanced and developing markets
Accelerating new medicine introduction in developing world & overcoming challenges
Explaining how to use the data sources and observational research for effective safety analysis
